Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Noticias Ir al feed de noticias
Clearmind Medicine: CMND-100 meets primary endpoint in Phase I/IIa study
Clearmind Medicine reports that the drug candidate CMND-100 met the primary endpoint for safety and tolerability in an FDA‑approved Phase I/IIa study for the treatment of alcohol use disorders. The third cohort showed a strong safety profile with no serious adverse events, even at higher doses, and the dose‑escalation phase confirmed good tolerability. The news boosted the share price (up about 15% to $1.43), and external analyses currently view the stock as trading below their estimated fair value, noting the company has more liquid assets than debt. » Más en de.investing.com
Datos financieros de la empresa
| (EUR) | abr 2026 | |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | -11,85 mil | 12,05 % |
| Beneficio neto | -1,75 M | 152,00 % |
| EBITDA | -1,33 M | 102,10 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 2,26 M € |
Número de acciones | 1,49 M |
Máximo/mínimo de 52 semanas | 452,27 € - 1,23 € |
| Dividendos | No |
Beta | -1,25 |
Ratio P/E | -0,15 |
Ratio PEG | 0,00 |
Ratio P/B | 0,05 |
Ratio P/S | 0,00 |
Perfil de la empresa
| Nombre | CLEARMIND MEDI.INC.O.N. |
| CEO | Adi Zuloff-Shani |
| Empleados | 4 |
Descubrir activos
Los accionistas de CLEARMIND MEDI.INC.O.N. también invierten en los siguientes activos
